Neurocrine Biosciences (NBIX) Receivables - Other (2019 - 2025)

Neurocrine Biosciences has reported Receivables - Other for 7 years, with the latest figure at $20.5 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Other rose 42.36% year-over-year to $20.5 million; the trailing twelve-month figure through Dec 2025 stood at $20.5 million (up 42.36% YoY), and the FY2025 full-year result was $20.5 million, up 42.36% from the prior year.
• Receivables - Other for Q4 2025 stood at $20.5 million, up from $14.4 million in the prior quarter.
• The five-year high for Receivables - Other was $20.5 million in Q4 2025, with the low at $2.2 million in Q4 2021.
• Historically, Receivables - Other has averaged $6.8 million across 5 years, with a median of $4.4 million in 2023.
• Annual changes were most pronounced in 2021 — Receivables - Other sank 40.54% — and 2024, when it jumped 186.36%.
• Neurocrine Biosciences' Receivables - Other stood at $2.2 million in 2021, then soared by 113.64% to $4.7 million in 2022, then surged by 138.3% to $11.2 million in 2023, then gained by 28.57% to $14.4 million in 2024, then soared by 42.36% to $20.5 million in 2025.
• The last three Receivables - Other figures came in at $20.5 million (Q4 2025), $14.4 million (Q4 2024), and $12.6 million (Q1 2024), per Business Quant data.